The gummies contain gelatin, so they may not be suitable for vegetarians or vegans
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
They can provide personalised advice based on your medical history and current health status
Table of Contents Understanding the Oral GLP1 Opportunity Reframing the Market: From Weight Loss to WholePerson Outcomes Messaging that Matters: Clarity, Context, and Credibility Channel Choices in a Multiformat Environment Addressing Access, Affordability, and Health Inequities Staying Honest About Safety and Expectations Measuring Success in a Complex Therapeutic Landscape FAQs Understanding the Oral GLP1 Opportunity The arrival of oral GLP1 therapies is transforming treatment pathways
Browse all Peptides & GLP-1 education An independent editorial review
While this adds to the cost, supervised programmes are far safer and more effective than self-administering injections sourced informally
